# US 2013/0158235 A1 · Selective manufacture of recombinant neurotoxin polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158235 A1
- Document ID: US20130158235A1
- Status: Published application
- Kind: A1
- Application number: 13/814,633
- Filed: 2011-08-10
- Published: 2013-06-20
- Earliest claimed: 2010-08-11
- Assignees: MERZ PHARMA GmbH & CO. KGaA
- Inventors: Swen Grein; Kerstin Hölscher; Tim Stoveken; Karl-Heinz Eisele
- Web page: https://patentgrep.com/patent/US20130158235A1

## CPC

- C07K 14/33: from Clostridium (G)
- C12N 9/52: derived from bacteria {or Archaea}
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/21: containing a His-tag
- C07K 2319/22: containing a Strep-tag
- C07K 2319/23: containing a GST-tag
- C07K 2319/24: containing a MBP (maltose binding protein)-tag
- C07K 2319/40: containing a tag for immunodetection, or an epitope for immunisation
- C07K 2319/41: containing a Myc-tag
- C07K 2319/43: containing a FLAG-tag
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention pertains to recombinant neurotoxin polypeptides and the manufacture thereof. Specifically, it relates to a polynucleotide encoding a neurotoxin polypeptide comprising a light chain, a linker and a heavy chain, wherein the linker is a modified linker comprising an heterologous amino acid sequence which confers at least one physicochemical property to the polypeptide which allows for separation of partially processed and/or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides, said heterologous amino acid sequence being flanked N- and C-terminally by a protease recognition and cleavage site Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the polynucleotide and methods for the manufacture of processed neurotoxin polypeptide.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A polynucleotide encoding a neurotoxin polypeptide comprising a light chain, a linker and a heavy chain, wherein the linker is a modified linker comprising a heterologous amino acid sequence which confers at least one physicochemical property to the polypeptide which allows for separation of partially processed or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides, wherein the heterologous amino acid sequence is flanked N and C-terminally by a protease recognition and cleavage site.

### Claim 23 (depends on 22)

The polynucleotide of claim 22, wherein the heterologous amino acid sequence binds with high affinity to a purification matrix.

### Claim 24 (depends on 22)

The polynucleotide of claim 22, wherein the heterologous amino acid sequence comprises a purification tag.

### Claim 25 (depends on 22)

The polynucleotide of claim 22, wherein the heterologous amino acid sequence increases the molecular weight of the neurotoxin polypeptide whereby the partially processed and/or unprocessed neurotoxin polypeptides can he physically separated from processed neurotoxin polypeptide.

### Claim 26 (depends on 22)

The polynucleotide of claim 22, wherein the heterologous amino acid sequence comprises (i) at least one amino acid domain conferring high affinity binding to a purification matrix and (ii) at least one amino acid domain which brings cysteine residues forming an intramolecular disulphide bridge between light and heavy chain in close proximity and/or prevents the heterologous amino acid sequence from interfering with the formation of proper disulfide bonds between the light and heavy chain.

### Claim 27 (depends on 26)

The polynucleotide of claim 26, wherein the at least one domain conferring high affinity binding to a purification matrix comprises a purification tag.

### Claim 28 (depends on 26)

The polynucleotide of claim 26, wherein the at least one amino acid domain which brings cysteine residues forming an intramolecular disulphide bridge between light and heavy chain in close proximity forms a three dimensional structure which brings the cysteine residues forming the intramolecular disulphide bridge between light and heavy chain in physical proximity.

### Claim 29 (depends on 28)

The polynucleotide of claim 28, wherein the three dimensional structure is formed by the C- and N-terminal amino acids of the heterologous amino acid sequence and is in the form of an antiparallel coiled coil or an antiparallel beta-sheet structure.

### Claim 30 (depends on 26)

The polynucleotide of claim 26, wherein the heterologous amino acid sequence further comprises at least one detectable marker amino acid sequence.

### Claim 31 (depends on 30)

The polynucleotide of claim 30, wherein the detectable marker amino acid sequence is selected from the group consisting of an amino acid sequence of a fluorescent protein, an amino acid sequence of an enzyme capable of generating a detectable signal, and an amino acid sequence of a detectable tag.

### Claim 32 (depends on 24)

The polynucleotide of claim 24, wherein the purification tag is selected from the group consisting of a His-tag, a Myc-tag, a FLAG-tag, a strep-tag, a MBP-tag, a NusA tag, a GST-tag, streptavidin and avidin.

### Claim 33 (depends on 22)

The polynucleotide of claim 22, wherein the protease recognition and cleavage site is selected from the group consisting of a neurotoxin light chain protease recognition and cleavage site from SNAP 25, a recognition and cleavage site from an E. coli protease, a Thrombin recognition and cleavage site, a Factor X recognition and cleavage site, a Trypsin recognition and cleavage site, an Enterokinase recognition and cleavage site, a TEV protease recognition and cleavage site, an HRV 3c recognition and cleavage site, and a PreScission Protease recognition and cleavage site.

### Claim 34 (depends on 22)

The polynucleotide of claim 22, wherein the light and heavy chain of the neurotoxin polypeptide are the light and heavy chain of a neurotoxin selected from the group consisting of BoNT/A, BoNT/B, BoNT/C1, BoNT/D, BoNT/E, BoNT/F, BoNT/G and TeNT.

### Claim 35 (depends on 22)

A vector comprising the polynucleotide of claim 22.

### Claim 36 (depends on 22)

A host cell comprising the polynucleotide of claim 22.

### Claim 37 (depends on 36)

The host cell of claim 36, wherein the host cell is a bacterial cell.

### Claim 38 (depends on 35)

A host cell comprising the vector of claim 35.

### Claim 39 (depends on 38)

The host cell of claim 38, wherein the host cell is a bacterial cell.

### Claim 40 (depends on 22)

A polypeptide encoded by the polynucleotide of claim 22.

### Claim 41 (depends on 40)

A method for the manufacture of a processed neurotoxin polypeptide comprising the steps of:
a) contacting an unprocessed neurotoxin polypeptide of claim 40 with a purification matrix under conditions and for a time sufficient for allowing binding of the the unprocessed neurotoxin polypeptide to the purification matrix;
b) contacting the unprocessed neurotoxin polypeptide bound to the purification matrix with a protease which is capable of cleaving the neurotoxin polypeptide at the protease recognition and cleavage sites resulting in processed and partially processed and/or unprocessed neurotoxin polypeptides; and
c) removing the released, processed neurotoxin polypeptide from the purification matrix.

### Claim 42 (depends on 40)

A method for the manufacture of a processed neurotoxin polypeptide comprising the steps of:
a) contacting a neurotoxin polypeptide of claim 40 with a protease which is capable of cleaving the neurotoxin polypeptide at the protease recognition and cleavage sites;
b) contacting the processed, unprocessed and/or partially processed neurotoxin polypeptide obtained in step a) with a purification matrix under conditions and for a time sufficient for allowing binding of the the unprocessed and/or partially processed neurotoxin polypeptide to the purification matrix; and
c) removing the released, processed neurotoxin polypeptide from the purification matrix.

### Claim 43 (depends on 42)

The method of claim 42, wherein step a) is carried out in a host cell or a lysate thereof' expressing the neurotoxin polynucleotide and a protease which is capable of cleaving the neurotoxin polypeptide at the protease recognition and cleavage sites.

### Claim 44 (depends on 40)

A method for the manufacture of processed neurotoxin polypeptide comprising the steps of:
a) contacting a neurotoxin polypeptide of claim 40 with a protease which is capable of cleaving the neurotoxin polypeptide at the protease recognition and cleavage sites;
b) subjecting the processed, unprocessed and/or partially processed neurotoxin polypeptide obtained in step a) to physical conditions for a time sufficient for allowing physical separation of partially processed or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides; and
c) removing processed neurotoxin polypeptide after the physical separation.
